Copaxone

Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Carcinoma in Situ + 1 more
Treatment
1 FDA approval
20 Active Studies for Copaxone

What is Copaxone

GlatiramerThe Generic name of this drug
Treatment SummaryGlatiramer acetate is a medication used to lower the frequency of relapses in people with relapsing-remitting multiple sclerosis. It is made up of four natural amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine. Its average molecular weight is 5,000-9,000 daltons. Glatiramer acetate works by changing the way the immune system responds to certain conditions.
Copaxoneis the brand name
image of different drug pills on a surface
Copaxone Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Copaxone
Glatiramer
2002
9

Approved as Treatment by the FDA

Glatiramer, otherwise known as Copaxone, is approved by the FDA for 1 uses such as Multiple Sclerosis .
Multiple Sclerosis
Helps manage Multiple Sclerosis

Effectiveness

How Copaxone Affects PatientsGlatiramer acetate is a mix of four amino acids (L-glutamic acid, L-alanine, L-tyrosine, and L-lysine) used to treat relapsing multiple sclerosis. Studies have shown that it can lower the number of annualized relapse rates compared to placebo and IFNb-1a. Some patients (roughly 16%) may experience side effects such as chest pain, injection site issues, or hepatic injury. Since it modifies the immune system, it may also interfere with immune function.
How Copaxone works in the bodyThe exact way that glatiramer acetate works is unknown, but it likely helps to treat multiple sclerosis (MS) by altering how the immune system works. MS is caused by damage to the myelin layer that surrounds nerves. Glatiramer acetate may bind to molecules on antigen-presenting cells that would otherwise cause inflammation. It also shifts the immune system from pro-inflammatory to anti-inflammatory and may promote the production of T-regulatory cells that help suppress MS.

When to interrupt dosage

The advised dosage of Copaxone is dependent upon the identified sickness. The measure fluctuates depending on the method of delivery (e.g. Solution - Subcutaneous or Injection, solution - Subcutaneous) pointed out in the table beneath.
Condition
Dosage
Administration
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Carcinoma in Situ
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Relapsing Remitting Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous

Warnings

Copaxone Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
There are 20 known major drug interactions with Copaxone.
Common Copaxone Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Antilymphocyte immunoglobulin (horse).
Apremilast
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Apremilast.
Copaxone Toxicity & Overdose RiskMice and rats given 15 times the recommended human dose of glatiramer acetate did not show an increase in cancer. Laboratory studies suggest that this drug does not cause mutations. Studies in animals have not revealed any negative effects on reproduction or development. If a person takes too much glatiramer acetate, they may experience severe side effects such as liver damage, loss of fatty tissues, or skin death near the injection site. If an overdose occurs, medical attention and supportive care are recommended.
image of a doctor in a lab doing drug, clinical research

Copaxone Novel Uses: Which Conditions Have a Clinical Trial Featuring Copaxone?

193 active clinical trials are presently assessing the therapeutic potential of Copaxone in treating Multiple Sclerosis.
Condition
Clinical Trials
Trial Phases
Multiple Sclerosis
127 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1
Carcinoma in Situ
3 Actively Recruiting
Not Applicable, Phase 4
Multiple Sclerosis
0 Actively Recruiting
Relapsing Remitting Multiple Sclerosis
14 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 4, Early Phase 1

Copaxone Reviews: What are patients saying about Copaxone?

5Patient Review
8/15/2015
Copaxone for Relapsing Form of Multiple Sclerosis
I was initially diagnosed in 1997 and have been on Avonex for 14 years. My new neurologist switched me to Copaxone, which I've found to be just as effective. I tolerate the injections well, with only minor pain at the injection site.
5Patient Review
4/11/2018
Copaxone for Relapsing Form of Multiple Sclerosis
I've been taking this medication for a week now, and I'm hoping to see more effects soon. So far, the side effect of slurred speech has made me look drunk at work and my bosses are starting to question me.
5Patient Review
5/26/2014
Copaxone for Multiple Sclerosis Symptoms Return then Become Less Severe
I'm really liking this treatment so far.
5Patient Review
6/29/2016
Copaxone for Relapsing Form of Multiple Sclerosis
I had to stop taking Copaxone for a pregnancy last year, and when my doctor recommended I start back up on the 40mg dose, I was really disappointed. The side effects were awful - bruising, lumps, stinging, etc. Shared Solutions is going to help with my copay, which is awesome because it's such an expensive drug.
4Patient Review
5/8/2014
Copaxone for Multiple Sclerosis Symptoms Return then Become Less Severe
I can only tell that this medication is working when I have my annual MRIs. From what I understand, Copaxone treats the disease but not the symptoms. However, I have seen an increase in my symptoms over the past two years while taking this drug.
3.7Patient Review
4/23/2014
Copaxone for Multiple Sclerosis Symptoms Return then Become Less Severe
The injection process is easy enough, but I experienced swelling and itching afterwards that felt like a bee sting. This would last up to two hours. Additionally, the swelling itself could last for 48 hours. After a few weeks of use, I developed mucous colitis which caused severe back and hip pain as well as flu-like symptoms.
3.7Patient Review
1/26/2016
Copaxone for Multiple Sclerosis Symptoms Return then Become Less Severe
Itching and uncomfortable knot in area of injection for 2 days afterwards. Worsening depression.
2Patient Review
1/17/2014
Copaxone for Multiple Sclerosis Symptoms Return then Become Less Severe
1Patient Review
1/31/2019
Copaxone for Relapsing Form of Multiple Sclerosis
I used to take this medication for my MS, but after a few years of use I went into anaphylactic shock. Please be aware that chest pain and other reactions are not normal side effects, no matter what you're told.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about copaxone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long can you stay on Copaxone?

"Copaxone is a long-term treatment that should be taken for as long as it is effective in reducing relapses for people with MS. The percentage of people who are relapse-free after two years is 34 to 56%."

Answered by AI

What are the side effects of Copaxone?

"-Reactions at the injection site may include: pain, itching, swelling, redness, discoloration, or lumps in the place where you have the injection. You may also experience flushing (temporary warmth, redness, or deepening of skin color), rash, shortness of breath, or chest pain."

Answered by AI

What type of drug is Copaxone?

"This medication is used to treat the symptoms of Multiple sclerosis. It may be either used by itself or in conjunction with other medications. It belongs to a class of drugs referred to as Immunomodulators; Multiple Sclerosis Treatments."

Answered by AI

Is Copaxone a good MS drug?

"Copaxone has been shown to be a moderately effective treatment for Duchenne muscular dystrophy in clinical trials, reducing the number of relapses by 30% compared to those taking placebos. Additionally, MRI scans of those taking Copaxone showed fewer new areas of active MS, or none at all."

Answered by AI

What does Copaxone actually do?

"An injectable drug called Glatiramer acetate, or Copaxone, is used to treat relapsing forms of multiple sclerosis in adults. This man-made version of a protein is similar to one found in myelin, which is an insulating layer that protects many of the nerves in your body. Copaxone blocks T cells that could potentially damage the myelin."

Answered by AI

What kind of drug is Copaxone?

"Copaxone is a prescription medicine that is used to treat the symptoms of Multiple sclerosis. It may be used alone or with other medications. Copaxone belongs to a class of drugs called Immunomodulators. It is not known if it is safe and effective to use in children."

Answered by AI

Clinical Trials for Copaxone

Image of Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo in Buffalo, United States.

Mindset Training for MS

18 - 65
All Sexes
Buffalo, NY
People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous research on cognitive rehabilitation has shown that regular training focused on memory and concentration can have positive effects on cognitive functioning, including processing speed, memory, and executive functions that support daily activities. Moreover, fMRI studies (brain scans that measure brain activity) have revealed changes in brain activation following cognitive rehabilitation. Recently, the idea has emerged that a more personalized approach could improve treatment outcomes. Specifically, researchers have identified a link between personality traits and cognitive functioning. Since every individual is different, current cognitive rehabilitation programs often fail to take these personal differences into account. In this project, the investigators aim to enhance the effectiveness of cognitive rehabilitation by focusing more closely on individual characteristics through an app-based training program. Participants will complete a 12-week app training prior to a 6-week cognitive rehabilitation program. The first app focuses on mindset training, supported by a coach. Afterwards, all participants will use a second app designed to train processing speed and memory. In addition to cognitive functioning, the investigators will also examine psychological, (neuro)biological, and social changes using questionnaires and fMRI. This research may provide valuable insights into how cognitive functioning and quality of life in people with MS can be improved. This study is funded by the National MS Fund and is a collaboration between several institutions: the Department of Health, Medical and Neuropsychology at Leiden University (The Netherlands), the University at Buffalo (USA), and Reha Rheinfelden (Switzerland).
Recruiting
New This Month
Jacobs School of Medicine and Biomedical Sciences, Neurology, University at BuffaloRalph HB Benedict, Prof
Have you considered Copaxone clinical trials? We made a collection of clinical trials featuring Copaxone, we think they might fit your search criteria.Go to Trials
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Image of John D. Dingell VA Medical Center in Detroit, United States.

Ocrelizumab for Multiple Sclerosis

18 - 75
All Sexes
Detroit, MI
This study seeks to assess the effects of long-term ocrelizumab therapy on fatigue (extreme tiredness) as well as cognition (thinking and reasoning skills, such as memory, learning and attention), in veterans with multiple sclerosis. The evaluation will involve cognitive assessment scales (to assess memory, attention and learning abilities), clinical evaluations (to assess nerve function and ability to move), and patient-reported outcome measures (in which you will answer questions about your tiredness, sleep and how you function in daily life). These assessments will occur at baseline (visit 1), 6 month (Visit-2) and 12 months (visit 3) to track changes over time.
Waitlist Available
Has No Placebo
John D. Dingell VA Medical CenterGenentech, Inc.
Image of Toronto Rehabilitation Institute in Toronto, Canada.

Balance Training with Electrical Stimulation for Multiple Sclerosis

18 - 65
All Sexes
Toronto, Canada
This study will evaluate the effects of combining balance training with electrical stimulation techniques in individuals with Multiple Sclerosis (MS). MS commonly impairs leg strength, coordination, and balance, increasing the risk of falls and reducing independence. The interventions include:Balance training only, Balance training with Functional Electrical Stimulation (FES), and Balance training with FES and Transcutaneous Spinal Cord Stimulation (TSCS). FES delivers small electrical pulses to leg muscles, while TSCS delivers electrical signals through the skin to stimulate the spinal cord and enhance motor control. The study will enroll up to 24 participants over a 3-year period. This trial is funded by MS Canada. Participants will be randomly assigned to one of three groups: (1) balance training only, (2) balance training with FES, or (3) balance training with FES and TSCS. All participants will complete 12 supervised training sessions over 6 weeks. During each session, participants will engage in interactive balance games while standing in a safety harness.Outcome assessments will be conducted at three time points: baseline (prior to training), post-intervention (after 6 weeks), and follow-up (8 weeks after training). Assessments will include: * Clinical tests of mobility and balance (Timed Up and Go:TUG, 10-Meter Walk Test:10MWT, Berg Balance Scale:BBS) * Computerized balance testing using a force plate * Questionnaires on walking ability, fear of falling, and balance confidence * Neurophysiological measures of brain-spinal cord-muscle communication before and after training
Waitlist Available
Senior-friendly
Toronto Rehabilitation Institute
Image of Disability Participation and Quality of Life (DPQOL) Laboratory in Urbana, United States.

Fall Prevention Program for Multiple Sclerosis

18+
All Sexes
Urbana, IL
The research team is conducting a study to determine if a fall prevention program designed specifically for people who use wheelchairs and scooters can help people better prevent and manage falls compared to the standard of care. This study will compare two groups of participants: 1. One group will use the iROLL-O+ app, which offers personalized fall prevention tools and strategies. 2. The other group will receive fall prevention information from a well-known program developed by the Centers for Disease Control and Prevention (CDC), called STEADI, which stands for Stopping Elderly Accidents, Deaths, and Injuries. This study includes adults living with Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) who use a wheelchair or scooter every day. The research team aims to determine which approach is more effective in reducing falls and improving confidence in performing daily activities.
Waitlist Available
Has No Placebo
Disability Participation and Quality of Life (DPQOL) Laboratory
Have you considered Copaxone clinical trials? We made a collection of clinical trials featuring Copaxone, we think they might fit your search criteria.Go to Trials
Image of Brigham & Women's Hospital in Boston, United States.

[F-18]FDG-PET for MS

18 - 70
All Sexes
Boston, MA
Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS and relapsing-remitting MS (RRMS), as well as healthy controls. PET will be compared to magnetic resonance imaging (MRI) lesion load and brain atrophy, and serum and blood biomarkers, as well as clinical measures of physical disability, cognitive impairment, fatigue, and depression. This study's findings may pave a path for integrating \[F-18\]FDG-PET in routine clinical practice for MS, improving patient experiences and outcomes. The specific aims of the study are: Aim 1: To compare glucose consumption in the brain in subjects with progressive MS, relapsing-remitting MS (RRMS), and healthy controls, using the radiolabeled glucose analogue 18-fluorodeoxyglucose, also known as \[F-18\]FDG. Aim 2: To compare the relationship between FDG-PET and standard 3T MRI measures including global and regional brain atrophy and lesion load, and to compare FDG-PET with MRI in terms of their relationship with clinical measures of physical disability, cognitive impairment, fatigue and depression in MS subjects. Aim 3: To assess the relationship of FDG-PET with serum and blood biomarkers, including but not limited to sNfL, GFAP, IL-6, and TNFα in MS.
Phase 4
Waitlist Available
Brigham & Women's HospitalTarun Singhal, MD, MBBSGenzyme, a Sanofi Company
Image of Mayo Clinic in Rochester, United States.

Autonomic Function Testing for Multiple Sclerosis

18 - 50
All Sexes
Rochester, MN
This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.
Recruiting
Has No Placebo
Mayo Clinic
Have you considered Copaxone clinical trials? We made a collection of clinical trials featuring Copaxone, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security